BridgeBio Pharma Inc. (BBIO) Tops Q2 EPS by 30c

BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q2 EPS of ($0.66), $0.30 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $54.02 million versus the consensus estimate of $29.12 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• Alimentation Couche-Tard Inc (ATD/B:CN) (ANCUF) PT Raised to Cdn$104 at UBS